Karyopharm to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announces senior management participation in investor conferences in November, including Jefferies 2023 London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts and slides available on company website.

NEWTON, Mass., Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:

Jefferies 2023 London Healthcare Conference
Format: Fireside chat
Date: Wednesday, November 15, 2023
Time: 8:00 a.m. ET / 1:00 p.m. GMT

Piper Sandler 35th Annual Healthcare Conference
Format: Fireside chat
Date: Wednesday, November 29, 2023
Time: 4:00 p.m. ET

A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following each presentation. 

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301980727.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What conferences will Karyopharm Therapeutics Inc. participate in November 2023?

Karyopharm Therapeutics Inc. will participate in the Jefferies 2023 London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference.

Where can I access the live webcasts and slides of the events?

The live webcasts and slides can be accessed on the Investor section of the Company's website at http://investors.karyopharm.com/events-presentations.

How long will the webcasts be available for replay?

The webcasts will be available for replay for 90 days following each presentation.